8/11/2020 8:41:05 AM
Revance Therapeutics Announces Publication Of Two
separate Peer-reviewed Articles In Dermatologic Surgery
5/19/2020 8:07:05 AM
Revance Agrees To Acquire HintMD And Its Proprietary Fintech Platform For Aesthetic Practices
5/1/2020 8:33:48 AM
Revance And Mylan Biosimilar To BOTOX(r) Program Decision To Extend Beyond April 30, 2020
2/6/2020 8:16:24 AM
Revance Therapeutics Says BLA For DAXI In Treatment Of Moderate To Severe Glabellar Lines Accepted For Review By US FDA
12/4/2019 7:45:59 AM
Revance Therapeutics Prices Public Offering Of 6.5 Mln Shares At $17/Shr
12/3/2019 4:08:08 PM
Revance Announces Proposed Public Offering Of Common Stock
12/2/2019 8:14:30 AM
Revance Therapeutics Promotes Dustin Sjuts To Role Of Chief Commercial Officer, Aesthetics & Therapeutics
11/25/2019 8:04:59 AM
Revance Submits BLA To The FDA For DAXI To Treat Glabellar (Frown) Lines
11/4/2019 8:06:21 AM
Revance Announces Publication Of SAKURA 1 And SAKURA 2 Results In Plastic And Reconstructive Surgery
10/14/2019 8:12:21 AM
Revance Appoints Mark Foley As President And CEO, Replacing Dan Browne
1/22/2019 4:10:02 PM
Revance Announces Closing Of Public Offering Of Common Stock
1/17/2019 6:53:06 AM
Revance Therapeutics Prices Public Offering Of 5.88 Mln Shares At $17.00 Per Share
12/4/2018 8:09:25 AM
Revance Therapeutics Enters License Agreement With Fosun Pharma Industrial
10/11/2018 8:33:24 AM
Revance Therapeutics Appoints Tobin Schilke As CFO